Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 ...

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether AstraZeneca PLC or Corcept Therapeutics Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...

Xponance Inc. raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 6.9% during the fourth quarter, ...

For this article, we used a Finviz screener to filter all the available ADR stocks. Then we compare the list with our Q4 2024 ...

Independent Advisor Alliance increased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.0% in the fourth quarter, according to the company in its most recent disclosure with the ...

Cytokinetics has a strong cash runway but faces risks from its Royalty Pharma deal. Read more on what's ahead for this biotech and its assets.

We forecast revenue declines to begin in 2026 for Farxiga and 2032 for Tagrisso. We estimate a cost of capital of 7.1%, which is consistent with those of pharmaceutical peers. We view AstraZeneca ...

and dapagliflozin (Farxiga; AstraZeneca). Amazingly, said Perera, medical therapy has evolved further since the publication of the REVIVED-BCIS2 trial results 30 months ago. “I think the clinical ...